Item has been added

Skip to content

For your health and well-being

Reliability and innovation at the service of your health.

🚛 FREE SHIPPING for orders over €25 🚛

Get in touch with us!


Lalbaay Monophasic

€149,00
Unit price  per 

Food for special medical purposes, intended for the dietary management of drug-resistant epilepsies .

The microbiota controls the metabolism of Tryptophan (TRP) : an altered microbiota has been reported in epileptic patients, caused by a deficiency of TRP. Therefore, restoring a correct microbiota allows not only to increase plasma TRP but also to restore its correct metabolism and its cerebral uptake, in order to promote a correct production of serotonin .

Confirming the role of serotonin, A reduced ability to derive TRP from the diet has been reported in epileptic patients (nutritional vulnerability), which may also depend on its altered metabolism with a greater production of indole catabolites, which perform reinforcing actions on the intestinal membrane. In particular, in epileptic patients a reduction of one third of the speed of synthesis of cerebral serotonin has been estimated compared to controls.

The 1990s saw a reversal of the role of serotonin in epilepsy: erroneously thought to be pro-convulsant, it was revealed to be anti-convulsant.

Since serotonin is synthesized from TRP, an essential amino acid (which comes only from the diet), which competes with other Large Neutral Amino Acids (LNAAs) for both brain uptake and intestinal absorption, dietary strategies aimed at increasing both plasma TRP and its brain uptake are useful.

Oral intake of serum protein alpha-lactalbumin has been shown to increase the plasma TRP/LNAAs ratio, but, in the presence of an altered TRP metabolism, this increase does not automatically correspond to an increase in its cerebral uptake (less than 1% of plasma TRP is available for cerebral uptake) and therefore to an increase in cerebral serotonin synthesis.

Thanks to its specific actions on the digestive system, alpha-lactalbumin has been shown to be capable of both modify the microbiota both of increase the rate of brain serotonin synthesis by up to five times . Alpha-lactalbumin It was also found to be able to increase the neuropeptide Y , which has been defined as a powerful endogenous anticonvulsant .

In addition, nourishing the cells of the digestive system well facilitates their response to alpha-lactalbumin stimulation. The specific nutrients of these cells are short chain fats (Short Chain Fatty Acids, SCFAs) which have an anti-inflammatory action , are able to improve the metabolism of the precursors of tryptophan and serotonin and regulate the functionality of the gut-brain axis at 360 degrees. Butyric acid , one of the most widespread SCFA, contributes to the correct functioning of the intestinal mucosa , positively influences the ecosystem of the gastrointestinal tract and has been shown to have anticonvulsant effects in several experimental models of epilepsy, positively influencing both the frequency of the crises themselves that aspects related to neuropsychiatric disorders .

The patented synergistic association between alpha-lactalbumin and butyric acid has led to the development of Lalbaay , the first food for special medical purposes patented and studied in Italy by reference centers in the field of epilepsy, to provide an effective and useful tool for the dietary management of drug-resistant epilepsies.

Guaranteed safe & secure checkout

    Payment methods
  • American Express
  • Apple Pay
  • Google Pay
  • Klarna
  • Maestro
  • Mastercard
  • PayPal
  • Visa
Lalbaay Monophasic

FORMAT and CONTENT

Box of 60 sachets of 4 g

Net content 240 g

INGREDIENTS

Maltodextrin, alpha-lactalbumin (contains milk derivatives), sodium butyrate, inulin, fructooligosaccharides, flavourings, sweetener: sucralose; emulsifier: polysorbate 80.

AVERAGE CONTENT OF CHARACTERIZING INGREDIENTS

Contents per 4g sachet:

Alpha-lactalbumin: 1 g

Sodium Butyrate: 0.6 g

Inulin: 0.4 g

Fructooligosaccharides (FOS): 0.3 g

NUTRITIONAL VALUES

Contents per ready dose (4g in 150ml):

Energy: 13 kcal

Fat: 0 g

  of which Saturated fat: 0 g

Carbohydrates: 2.1 g

  of which sugars: 0.1 g

Fiber: 0g

Protein: 0.9 g

Salt: 0.3 g*
*Salt is due exclusively to naturally present sodium.

CLAIMS and INDICATIONS

Food for special medical purposes for the dietary treatment of drug-resistant epilepsy.

The synergistic association between Alpha-lactalbumin and Butyric acid allows to act effectively on the Microbiota-Intestine-Brain axis. The intestinal microbiota plays a fundamental role in the metabolism of tryptophan (TRP). In epileptic patients, an altered microbiota can cause a TRP deficiency, leading to a reduced production of cerebral serotonin. Alpha-lactalbumin helps to modify the microbiota and improve the metabolism of TRP, increasing the synthesis of serotonin and neuropeptide Y, which has anticonvulsant effects. Butyric acid also plays a fundamental role in maintaining the gastrointestinal ecosystem, promoting the reduction of epileptic seizures and the control of neuropsychiatric disorders.

DOSAGE and HOW TO USE

It is recommended to take 1-2 sachets per day, or according to the doctor's advice, away from protein meals, preferably 12 hours apart. Pour the contents of one sachet into a glass and then add water (about 150 ml). Mix until completely dissolved.

The sachet should be consumed on an empty stomach (or at least 15-20 minutes before meals). 

WARNINGS

The product must be used under medical supervision.

Not for parenteral use.

It is not suitable to be used as a sole source of nutrition.

Keep out of reach of children under 3 years of age.

STORAGE METHODS

Store in a cool, dry place, away from light and heat sources.

The expiry date refers to the product stored correctly, in intact packaging.